Impacto en la valoración funcional y calidad de vida en pacientes con insuficiencia cardiaca en una IPS de Barranquilla (Atl, Co) durante el 2022

datacite.rightshttp://purl.org/coar/access_right/c_16ecspa
dc.contributor.advisorGómez Giraldo, Luisa Maria
dc.contributor.advisorGonzález Torres, Henry Joseth
dc.contributor.authorMolina Higgins, Rodrigo Alfonso
dc.contributor.authorRusell Hernández, Margareth Teresita De Jesús
dc.date.accessioned2024-01-16T22:21:34Z
dc.date.available2024-01-16T22:21:34Z
dc.date.issued2023
dc.description.abstractLa insuficiencia cardíaca (IC) es una causa importante de morbilidad y mortalidad en todo el mundo de allí es la importancia de la implementación de programas que se enfoquen en cambiar hábitos acompañados de un equipo integral y multidisciplinar. Objetivo: Evaluar el impacto en la recuperación de la valoración funcional y calidad de vida en pacientes con Insuficiencia Cardiaca adscritos a un programa de seguimiento y control de una IPS de Barranquilla (Atl, CO) durante el 2022. Metodología: Se realizó un estudio analítico, recogiendo los datos de evaluación de los pacientes adscritos a un programa de seguimiento y control de IC clasificados por NYHA, la valoración funcional por Barthel y calidad de con EQ-5D. Para describir los datos se utilizaron medidas de tendencia central y dispersión para variables cuantitativas, y frecuencias para variables categóricas. Se emplearon pruebas de Wilcoxon y Fisher exact test, considerando p < 0.05 como significativo. El análisis se realizó en R-CRAN versión 4.3.0. Resultados: Se enrolaron 83 pacientes con IC, el 67% eran hombres, la edad media fue de 60 años. La HTA afectó al 47%, y la DM2 al 22%. La etiología dilatada fue la más común (55%). La mayoría estaba en NYHA clase II-IV y en estadio C según ACC/AHA. El BARTHEL promedió 90, indicando moderada dependencia. El EQ-5D promedió 80, denotando un estado de salud óptimo 12 posterior al inicio del programa. Hubo mejoras significativas en la FEVI y la puntuación EQ-5D a los 12 meses. No se observaron cambios en otros parámetros clínicos.spa
dc.description.abstractHeart failure (HF) is a significant cause of global morbidity and mortality, emphasizing the importance of implementing programs that focus on lifestyle modifications with the support of a comprehensive and multidisciplinary team. Objective: To assess the impact on functional assessment and quality of life recovery in patients with Heart Failure enrolled in a monitoring and control program at a healthcare institution in Barranquilla (Atl, CO) during 2022. Methodology: An analytical study was conducted, collecting data from the evaluation of patients enrolled in a Heart Failure monitoring and control program classified by NYHA, functional assessment using Barthel, and quality of life with EQ-5D. Descriptive statistics were used for quantitative variables, including measures of central tendency and dispersion, while frequencies were used for categorical variables. Wilcoxon and Fisher exact tests were employed, considering p < 0.05 as significant. The analysis was performed in R-CRAN version 4.3.0. Results: 83 patients with HF were enrolled, 67% were male, and the mean age was 60 years. Hypertension affected 47%, and type 2 diabetes mellitus affected 22%. Dilated etiology was the most common (55%). The majority were in NYHA class II-IV and stage C according to ACC/AHA. The BARTHEL averaged 90, indicating moderate dependency. The EQ-5D averaged 80, indicating an optimal health status 12 months after program initiation. Significant improvements were observed in LVEF and EQ-5D score at 12 months. No changes were observed in other clinical parameters.eng
dc.format.mimetypepdfspa
dc.identifier.urihttps://hdl.handle.net/20.500.12442/13792
dc.language.isospaspa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias de la Saludspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectInsuficiencia cardíacaspa
dc.subjectPrograma de seguimientospa
dc.subjectEvaluación funcionalspa
dc.subjectCalidad de vidaspa
dc.subjectManejo de la enfermedadspa
dc.subjectResultado del tratamientospa
dc.subjectHeart failureeng
dc.subjectFollow-up programeng
dc.subjectFunctional assessmenteng
dc.subjectQuality of lifeeng
dc.subjectDisease managementeng
dc.subjectTreatment outcomeeng
dc.titleImpacto en la valoración funcional y calidad de vida en pacientes con insuficiencia cardiaca en una IPS de Barranquilla (Atl, Co) durante el 2022spa
dc.type.driverinfo:eu-repo/semantics/otherspa
dc.type.spaOtrosspa
dcterms.referencesMalik A, Brito D, Vaqar S, Chhabra L. Congestive Heart Failure [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28785469eng
dcterms.referencesWatson RD, Gibbs CR, Lip GY. ABC of heart failure. Clinical features and complications. BMJ [Internet]. 2000 Jan 22;320(7229):236–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10642237eng
dcterms.referencesGonzález-Juanatey JR, Alegría Ezquerra E, Bertoméu Martínez V, Conthe Gutiérrez P, de Santiago Nocito A, Zsolt Fradera I. [Heart failure in outpatients: comorbidities and management by different specialists. The EPISERVE Study]. Rev Esp Cardiol. 2008 Jun;61(6):611–9.eng
dcterms.referencesMughal MS, Ghani AR, Kumar S, Hanif W, Ahsan I, Akbar H, et al. Heart Failure Patients and Implications of Obesity: A Single-Center Retrospective Study. Cureus [Internet]. 2021 Sep;13(9):e18140. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34703681eng
dcterms.referencesLee H, Oh S-H, Cho H, Cho H-J, Kang H-Y. Prevalence and socio-economic burden of heart failure in an aging society of South Korea. BMC Cardiovasc Disord [Internet]. 2016 Nov 10;16(1):215. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27832754eng
dcterms.referencesDe La Fuente Cid R, Hermida Ameijeiras A, Pazo Núñez M, Lado Lado F. Epidemiología de la insuficiencia cardiaca. Proporciones de epidemia. An Med Interna. 2007;24(10):500–4.spa
dcterms.referencesHessel FP. Overview of the socio-economic consequences of heart failure. Cardiovasc Diagn Ther [Internet]. 2021 Feb;11(1):254–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33708497eng
dcterms.referencesBosch X, Alfonso F, Bermejo J. Avances en la evaluación diagnóstica y terapéutica de la insuficiencia cardíaca. Del tratamiento tónico-deplectivo al trasplante celular y la regeneración miocárdica. Rev Española Cardiol [Internet]. 2004 Feb;57(2):161–2. Available from: http://www.revespcardiol.org/cgi- bin/wdbcgi.exe/cardio/mrevista_cardio.fulltext?pident=13057267spa
dcterms.referencesPereira-Rodríguez JE, Gina Rincón-González Lic Damaris Niño-Serrato LR, -Inglés E, Pereira-Rodríguez J. Insuficiencia cardíaca: Aspectos básicos de una epidemia en aumento. Soc Cuba Cardiol. 2016;8(1):58–70.spa
dcterms.referencesVinueza G, Chiluisa A, Aveiga C. Insuficiencia cardíaca: desafíos en la terapia farmacológica. Rev Digit Postgrado [Internet]. 2019;8(3):1–7. Available from: http://saber.ucv.ve/ojs/index.php/rev_dp/article/view/17078spa
dcterms.referencesTratamiento farmacológico de la insuficiencia cardíaca. ¿Qué hay de nuevo? Rev Uruguaya Cardiol [Internet]. 2017 Dec 22;32(3). Available from: http://www.suc.org.uy/revista/V32N3/pdf/rcv32n3_ic-komajda.pdfspa
dcterms.referencesMercedes A, Villero U, Del K, Marín C, Andrés C, Criado R. Manejo de la falla cardiaca aguda en urgencias: enfoque terapia farmacológica. Medicas UIS. 2013;26(1):69–79.spa
dcterms.referencesHerreros J, Trainini JC, Bernal JM, Gutiérrez F, Cabo J, Chachques JC. Tratamiento de la insuficiencia cardíaca: nuevas estrategias terapéuticas. Cirugía Cardiovasc [Internet]. 2011 Apr;18(2):113–20. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1134009611700651spa
dcterms.referencesPlácido R, Mebazaa A. Tratamiento no farmacológico de la insuficiencia cardiaca aguda. Rev Española Cardiol [Internet]. 2015 Sep;68(9):794–802. Available from: https://linkinghub.elsevier.com/retrieve/pii/S030089321500305Xspa
dcterms.referencesO’Connor C, Fiuzat M, Mulder H, Coles A, Ahmad T, Ezekowitz JA, et al. Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. Eur J Heart Fail [Internet]. 2019 Jun;21(6):770–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30919549eng
dcterms.referencesChaney E, Shaw A. Pathophysiology of Fluid Retention in Heart Failure. In 2010. p. 46–53. Available from: https://www.karger.com/Article/FullText/313720eng
dcterms.referencesSegovia Cubero J, Alonso-Pulpón Rivera L, Peraira Moral R, Silva Melchor L. Heart Failure: Etiology and Approach to Diagnosis. Rev Española Cardiol (English Ed [Internet]. 2004 Mar;57(3):250–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1885585706601436eng
dcterms.referencesKamimura D, Cain LR, Mentz RJ, White WB, Blaha MJ, DeFilippis AP, et al. Cigarette Smoking and Incident Heart Failure. Circulation [Internet]. 2018 Jun 12;137(24):2572–82. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.031912eng
dcterms.referencesGrubb AF, Greene SJ, Fudim M, Dewald T, Mentz RJ. Drugs of Abuse and Heart Failure. J Card Fail [Internet]. 2021 Nov;27(11):1260–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34133967eng
dcterms.referencesScherer PE, Hill JA. Obesity, Diabetes, and Cardiovascular Diseases: A Compendium. Circ Res [Internet]. 2016 May 27;118(11):1703–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27230636eng
dcterms.referencesGentile F, Castiglione V, De Caterina R. Coronary Artery Anomalies. Circulation [Internet]. 2021 Sep 21;144(12):983–96. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055347eng
dcterms.referencesFrescura C, Basso C, Thiene G, Corrado D, Pennelli T, Angelini A, et al. Anomalous origin of coronary arteries and risk of sudden death: a study based on an autopsy population of congenital heart disease. Hum Pathol [Internet]. 1998 Jul;29(7):689–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9670825eng
dcterms.referencesVilcant V, Hai O. Bacterial Endocarditis [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30760474eng
dcterms.referencesYallowitz AW, Decker LC. Infectious Endocarditis [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27672723eng
dcterms.referencesFahed AC, Roberts AE, Mital S, Lakdawala NK. Heart failure in congenital heart disease: a confluence of acquired and congenital. Heart Fail Clin [Internet]. 2014 Jan;10(1):219–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24275306eng
dcterms.referencesBhandari B, Quintanilla Rodriguez BS, Masood W. Ischemic Cardiomyopathy. StatPearls. 2023.eng
dcterms.referencesMaron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. JACC Heart Fail [Internet]. 2018 May;6(5):353–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29655822eng
dcterms.referencesDattoli-García CA, Jackson-Pedroza CN, Gallardo-Grajeda AL, Gopar-Nieto R, Araiza-Garygordobil D, Arias-Mendoza A. [Infarto agudo de miocardio: revisión sobre factores de riesgo, etiología, hallazgos angiográficos y desenlaces en pacientes jóvenes]. Arch Cardiol Mex [Internet]. 2021 Nov 1;91(4):485–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33471784spa
dcterms.referencesJenča D, Melenovský V, Stehlik J, Staněk V, Kettner J, Kautzner J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Hear Fail [Internet]. 2021 Feb;8(1):222–37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33319509eng
dcterms.referencesVarricchi G, Ameri P, Cadeddu C, Ghigo A, Madonna R, Marone G, et al. Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Front Physiol [Internet]. 2018;9:167. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29563880eng
dcterms.referencesXu Z, Cang S, Yang T, Liu D. Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy. Hematol Rep [Internet]. 2009 Mar 13;1(1):4. Available from: http://www.pagepress.org/journals/index.php/hr/article/view/hr.2009.e4eng
dcterms.referencesShalata W, Abu-Salman A, Steckbeck R, Mathew Jacob B, Massalha I, Yakobson A. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers (Basel) [Internet]. 2021 Oct 18;13(20). Available from: http://www.ncbi.nlm.nih.gov/pubmed/34680365eng
dcterms.referencesTang X-M, Chen H, Li Q, Song Y, Zhang S, Xu X-S, et al. Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC. Onco Targets Ther [Internet]. 2018;11:123–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29343971eng
dcterms.referencesNakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer [Internet]. 2005 Dec 1;104(11):2492–8. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cncr.21478eng
dcterms.referencesSpitzer E, Hahn RT, Pibarot P, de Vries T, Bax JJ, Leon MB, et al. Aortic Stenosis and Heart Failure: Disease Ascertainment and Statistical Considerations for Clinical Trials. Card Fail Rev [Internet]. 2019 May;5(2):99–105. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31179020eng
dcterms.referencesPujari SH, Agasthi P. Aortic Stenosis [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16980116eng
dcterms.referencesPatel JB, Borgeson DD, Barnes ME, Rihal CS, Daly RC, Redfield MM. Mitral regurgitation in patients with advanced systolic heart failure. J Card Fail [Internet]. 2004 Aug;10(4):285–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15309693eng
dcterms.referencesDouedi S, Douedi H. Mitral Regurgitation [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30060923eng
dcterms.referencesMulla S, Asuka E, Bora V, Siddiqui WJ. Tricuspid Regurgitation [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2345895eng
dcterms.referencesDesai DS, Hajouli S. Arrhythmias. StatPearls. 2023.eng
dcterms.referencesHafeez Y, Grossman SA. Sinus Bradycardia. StatPearls. 2023.eng
dcterms.referencesRuddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol [Internet]. 2017 Sep;24(14):1555–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28617620eng
dcterms.referencesNesheiwat Z, Goyal A, Jagtap M. Atrial Fibrillation. StatPearls. 2023.eng
dcterms.referencesChhabra L, Goyal A, Benham MD. Wolff-Parkinson-White Syndrome [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12807866eng
dcterms.referencesThyagarajan B, Alagusundaramoorthy SS, Agrawal A. Atrial Fibrillation Due to Over The Counter Stimulant Drugs in A Young Adult. J Clin Diagn Res [Internet]. 2015 Aug;9(8):OD05-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26435989eng
dcterms.referencesShahjehan RD, Bhutta BS. Coronary Artery Disease [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24811552eng
dcterms.referencesMathew P, Kaur J, Rawla P. Hyperthyroidism [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27521067eng
dcterms.referencesSmid J, Scherner M, Wolfram O, Groscheck T, Wippermann J, Braun-Dullaeus RC. Cardiogenic Causes of Fever. Dtsch Arztebl Int [Internet]. 2018 Mar 23;115(12):193–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29642989eng
dcterms.referencesCelano CM, Daunis DJ, Lokko HN, Campbell KA, Huffman JC. Anxiety Disorders and Cardiovascular Disease. Curr Psychiatry Rep [Internet]. 2016 Nov;18(11):101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27671918eng
dcterms.referencesLima G, Cardoso E, Fiscus G. Presumed Alcohol-Induced Ventricular Tachycardia Storm: A Case Report. Cureus [Internet]. 2020 May 13;12(5):e8097. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32542152eng
dcterms.referencesGuerri G, Krasi G, Precone V, Paolacci S, Chiurazzi P, Arrigoni L, et al. Cardiac conduction defects. Acta Biomed [Internet]. 2019 Sep 30;90(10-S):20–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31577249eng
dcterms.referencesKashou AH, Goyal A, Nguyen T, Ahmed I, Chhabra L. Atrioventricular Block [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30817991eng
dcterms.referencesScherbak D, Hicks GJ. Left Bundle Branch Block [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17385703eng
dcterms.referencesPérez-Riera AR, Barbosa-Barros R, de Rezende Barbosa MPC, Daminello-Raimundo R, de Abreu LC, Nikus K. Left bundle branch block: Epidemiology, etiology, anatomic features, electrovectorcardiography, and classification proposal. Ann Noninvasive Electrocardiol [Internet]. 2019 Mar;24(2):e12572. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29932265eng
dcterms.referencesVoigt JU, Abraham TP. Ischemic heart disease. ASE’s Comprehensive Strain Imaging. 2021. 168–187 p.eng
dcterms.referencesPahwa R, Jialal I. Atherosclerosis [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30975520eng
dcterms.referencesNdrepepa G. Atherosclerosis & ischaemic heart disease: Here to stay or gone tomorrow. Indian J Med Res [Internet]. 2017 Sep;146(3):293–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29355133eng
dcterms.referencesHermiz C, Sedhai YR. Angina [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29874661eng
dcterms.referencesOjha N, Dhamoon AS. Myocardial Infarction. StatPearls. 2023.eng
dcterms.referencesBustamante JG, Zaidi SRH. Amyloidosis [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30604309eng
dcterms.referencesAdam RD, Coriu D, Jercan A, Bădeliţă S, Popescu BA, Damy T, et al. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Hear Fail [Internet]. 2021 Aug;8(4):2380–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34089308eng
dcterms.referencesBelziti C, Bagnati R, Bianqui CT, Arbelbide J, Nucifora E, Domenech A, et al. Heart transplantation and bone marrow transplantation in a patient with AL amyloidosis and refractory heart failure . Rev Argent Cardiol [Internet]. 2009;77(4):309–11. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-76249084622&partnerID=40&md5=23ccdc65635d7764f546ec6f965a29c3eng
dcterms.referencesDecotto S, Villanueva E, Pérez de Arenaza D, Nucifora EM, Aguirre MA, Posadas-Martínez ML, et al. [Heart transplantation in amyloidosis. Clinical and imaging manifestations]. Arch Cardiol Mex [Internet]. 2022 Jul 1;92(3):320–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34619747eng
dcterms.referencesFrangogiannis NG. Cardiac fibrosis. Cardiovasc Res [Internet]. 2021 May 25;117(6):1450–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33135058spa
dcterms.referencesMorfino P, Aimo A, Castiglione V, Gálvez-Montón C, Emdin M, Bayes-Genis A. Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy. Heart Fail Rev [Internet]. 2023 Mar;28(2):555–69. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36221014eng
dcterms.referencesPorter JL, Rawla P. Hemochromatosis [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8696333eng
dcterms.referencesMetivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant [Internet]. 2000;15 Suppl 3:14–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11032352eng
dcterms.referencesOsuna PM, Udovcic M, Sharma MD. Hyperthyroidism and the Heart. Methodist Debakey Cardiovasc J [Internet]. 2017;13(2):60–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28740583eng
dcterms.referencesArnalich F, Plaza I, Sobrino JA, Oliver J, Barbado J, Peña JM, et al. Cardiac size and function in Paget’s disease of bone. Int J Cardiol [Internet]. 1984 Apr;5(4):491–505. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6233229eng
dcterms.referencesBouchette P, Boktor SW. Paget Disease [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30807433eng
dcterms.referencesMurphy SP, Ibrahim NE, Januzzi JL. Heart Failure With Reduced Ejection Fraction: A Review. JAMA [Internet]. 2020 Aug 4;324(5):488–504. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32749493eng
dcterms.referencesHajouli S, Ludhwani D. Heart Failure and Ejection Fraction [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27206819eng
dcterms.referencesVillar R. Escala NYHA ( New York Heart Association ) Escala NYHA ( New York Heart Association ). Med Interna (Bucur). 1994;eng
dcterms.referencesAlbert N, Trochelman K, Li J, Lin S. Signs and symptoms of heart failure: are you asking the right questions? Am J Crit Care [Internet]. 2010 Sep;19(5):443–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19940253eng
dcterms.referencesChopra S, Cherian D, Verghese PP, Jacob JJ. Physiology and clinical significance of natriuretic hormones. Indian J Endocrinol Metab [Internet]. 2013 Jan;17(1):83–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23776857eng
dcterms.referencesCorteville DCM, Bibbins-Domingo K, Wu AHB, Ali S, Schiller NB, Whooley MA. N-terminal pro-B-type natriuretic peptide as a diagnostic test for ventricular dysfunction in patients with coronary disease: data from the heart and soul study. Arch Intern Med [Internet]. 2007 Mar 12;167(5):483–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17353496eng
dcterms.referencesFelker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med [Internet]. 2000 Apr 13;342(15):1077–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10760308eng
dcterms.referencesJones NR, Hobbs FR, Taylor CJ. Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature. BJGP open [Internet]. 2017 Oct 4;1(3):bjgpopen17X101013. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30564675eng
dcterms.referencesCamm AJ, Savelieva I, Lip GYH, Guideline Development Group for the NICE clinical guideline for the management of atrial fibrillation. Rate control in the medical management of atrial fibrillation. Heart [Internet]. 2007 Jan;93(1):35–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16952972eng
dcterms.referencesBoldt L-H, Rolf S, Huemer M, Parwani AS, Luft FC, Dietz R, et al. Optimal heart failure therapy and successful cardioversion in heart failure patients with atrial fibrillation. Am Heart J [Internet]. 2008 May;155(5):890–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18440338eng
dcterms.referencesFaber TS, Zehender M. [Antiarrhythmic therapy in patients with heart failure]. Ther Umsch [Internet]. 2000 May;57(5):324–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10859993eng
dcterms.referencesGhimire R, Dhungana SP. Evaluation of drugs used in chronic heart failure at tertiary care centre: a hospital based study. J Cardiovasc Thorac Res [Internet]. 2019;11(2):79–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31384400eng
dcterms.referencesRosano GM, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev [Internet]. 2017 Apr;3(1):52–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28785476eng
dcterms.referencesPinho-Gomes AC, Rahimi K. Management of blood pressure in heart failure. Heart [Internet]. 2019 Apr;105(8):589–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30674544eng
dcterms.referencesAdamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Curr Heart Fail Rep [Internet]. 2009 Dec;6(4):287–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19948098eng
dcterms.referencesButler J, Talha KM, Aktas MK, Zareba W, Goldenberg I. Role of Implantable Cardioverter Defibrillator in Heart Failure With Contemporary Medical Therapy. Circ Hear Fail [Internet]. 2022 Aug;15(8). Available from: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.009634eng
dcterms.referencesAcena M, Regoli F, Auricchio A. Terapia de resincronización cardiaca. Indicaciones y contraindicaciones. Rev Española Cardiol [Internet]. 2012 Sep;65(9):843–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0300893212002527spa
dcterms.referencesSarsam L, Malik MB, Bashir K. Ultrafiltration in Acute Decompensated Heart Failure [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30815994eng
dcterms.referencesY Birati E, Jessup M. Left Ventricular Assist Devices in the Management of Heart Failure. Card Fail Rev [Internet]. 2015 Apr;1(1):25–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28785427eng
dcterms.referencesWesterdahl DE, Kobashigawa JA. Heart Transplantation for Advanced Heart Failure. In: Cardiac Intensive Care [Internet]. Elsevier; 2019. p. 504-524.e2. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780323529938000485eng
dcterms.referencesMurashita T. The role of coronary artery bypass grafting in patients with ischemic cardiomyopathy in the current era. J Thorac Dis [Internet]. 2016 Sep;8(9):E1032–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27747055eng
dcterms.referencesEnriquez-Sarano M, Schaff H V., Orszulak TA, Bailey KR, Tajik AJ, Frye RL. Congestive Heart Failure After Surgical Correction of Mitral Regurgitation. Circulation [Internet]. 1995 Nov;92(9):2496–503. Available from: https://www.ahajournals.org/doi/10.1161/01.CIR.92.9.2496eng
dcterms.referencesYamamoto K, Matsumura‐Nakano Y, Shiomi H, Natsuaki M, Morimoto T, Kadota K, et al. Effect of Heart Failure on Long‐Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Severe Coronary Artery Disease. J Am Heart Assoc [Internet]. 2021 Aug 3;10(15). Available from: https://www.ahajournals.org/doi/10.1161/JAHA.121.021257eng
dcterms.referencesMendiratta P, Schoo C, Latif R. Clinical Frailty Scale [Internet]. StatPearls. 2023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23395245eng
dcterms.referencesHuybrechts KF, Jaime Caro J. The Barthel Index and modified Rankin Scale as prognostic tools for long-term outcomes after stroke: a qualitative review of the literature. Curr Med Res Opin [Internet]. 2007 Jul 6;23(7):1627–36. Available from: http://www.tandfonline.com/doi/full/10.1185/030079907X210444eng
dcterms.referencesHerdman M, Badia X, Berra S. El EuroQol-5D: una alternativa sencilla para la medición de la calidad de vida relacionada con la salud en atención primaria. Atención Primaria. 2001;28(6):425–9.spa
dcterms.referencesSavarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev [Internet]. 2017 Apr;3(1):7–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28785469eng
dcterms.referencesKontogeorgos S, Thunström E, Johansson MC, Fu M. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study. Int J Cardiol [Internet]. 2017 Apr 1;232:86–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28100428eng
dcterms.referencesSun LY, Tu J V, Bader Eddeen A, Liu PP. Prevalence and Long-Term Survival After Coronary Artery Bypass Grafting in Women and Men With Heart Failure and Preserved Versus Reduced Ejection Fraction. J Am Heart Assoc [Internet]. 2018 Jun 16;7(12). Available from: http://www.ncbi.nlm.nih.gov/pubmed/29909401eng
dcterms.referencesShahim B, Kapelios CJ, Savarese G, Lund LH. Global Public Health Burden of Heart Failure: An Updated Review. Card Fail Rev [Internet]. 2023;9:e11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37547123eng
dcterms.referencesDíez-Villanueva P, Jiménez-Méndez C, Alfonso F. Heart failure in the elderly. J Geriatr Cardiol. 2021 Mar;18(3):219–32.eng
dcterms.referencesGina González Robledo, , Mónica Jaramillo Jaramillo JCC. Diabetes mellitus, insuficiencia cardiaca y enfermedad renal crónica. Rev Colomb Cardiol. 2020;27:3–6.spa
dcterms.referencesKhan MS, Samman Tahhan A, Vaduganathan M, Greene SJ, Alrohaibani A, Anker SD, et al. Trends in prevalence of comorbidities in heart failure clinical trials. Eur J Heart Fail. 2020 Jun;22(6):1032–42.eng
dcterms.referencesWu J-R, Lennie TA, Frazier SK, Moser DK. Health-Related Quality of Life, Functional Status, and Cardiac Event-Free Survival in Patients With Heart Failure. J Cardiovasc Nurs. 2016;31(3):236–44.eng
dcterms.referencesVicent L, Álvarez-García J, Vazquez-Garcia R, González-Juanatey JR, Rivera M, Segovia J, et al. Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction. J Clin Med. 2023 Apr;12(8).eng
dcterms.referencesLawson CA, Solis-Trapala I, Dahlstrom U, Mamas M, Jaarsma T, Kadam UT, et al. Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. PLoS Med. 2018 Mar;15(3):e1002540.eng
dcterms.referencesStrini V, Piazzetta N, Gallo A, Schiavolin R. Barthel Index: creation and validation of two cut-offs using the BRASS Index. Acta Biomed. 2020 Mar;91(2-S):19–26.eng
dcterms.referencesJonsson Å, Orwelius L, Dahlstrom U, Kristenson M. Evaluation of the usefulness of EQ-5D as a patient-reported outcome measure using the Paretian classification of health change among patients with chronic heart failure. J patient-reported outcomes. 2020 Jun;4(1):50.eng
dcterms.referencesKosaraju A, Goyal A, Grigorova Y, Makaryus AN. Left Ventricular Ejection Fraction. StatPearls. 2023.eng
dcterms.referencesGandara-Ricardo JA, Muñoz Ortiz E, Aguilar Molina OE, Garcia Rueda K, Giraldo Ramirez S, Salamanca JF, et al. Tratamiento actual de la falla cardiaca con fracción de expulsión reducida. Acta Médica Colomb. 2021 Apr;46(4).spa
dcterms.referencesKataoka H. Clinical characteristics of lower-extremity edema in stage A cardiovascular disease status defined by the ACC/AHA 2001 Chronic Heart Failure Guidelines. Clin Cardiol. 2013 Sep;36(9):555–9.eng
oaire.versioninfo:eu-repo/semantics/acceptedVersionspa
sb.programaEspecialización en Medicina Internaspa
sb.sedeSede Barranquillaspa

Archivos

Bloque original
Mostrando 1 - 2 de 2
Cargando...
Miniatura
Nombre:
PDF_Resumen
Tamaño:
213.94 KB
Formato:
Adobe Portable Document Format
No hay miniatura disponible
Nombre:
PDF.pdf
Tamaño:
577 KB
Formato:
Adobe Portable Document Format

Colecciones